Transcription of Regulatory Perspective for Companion Diagnostics
{{id}} {{{paragraph}}}
Example: bankruptcy
Regulatory Perspective for Companion Diagnostics
Regulatory Perspective for Companion DiagnosticsThe 38thAnnual Midwest Biopharmaceutical Statistical Workshop (MBSW)May 19, 2015 Jennifer Shen, , RACFood and Drug Administration (FDA)Center for Devices and Radiological Health (CDRH)Office of In Vitro Diagnostics and Radiological Health (OIR)Division of Immunology and Hematology Devices (DIHD) Hematology and coagulation tests Tests for immunological disease Flow cytometryDivision of Chemistry and Toxicology Devices (DCTD) General and specialized chemistry tests ( , neonatal biochemical screening tests, endocrine tests, and tests for women's health) Drug of abuse tests Therapeutic drug monitoring testsDivision of Microbiology Devices (DMD) Detection of microorganisms (bacteria, fungi, mycobacteria, viruses) by chemical, immunological, and nucleic acid amplification methods Biothreat agents New and emerging infectious diseasesDivision of Molecular Genetics a
Division of Immunology and Hematology Devices (DIHD) • Hematology and coagulation tests • Tests for immunological disease • Flow cytometry
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
Quality Assessment in Medical, Quality Assessment in Medical Laboratories" Laboratories" --differences differences, Establishing and Applying Critical Quality, QUALITY, Laboratory Accreditation Manual, Laboratory Accreditation Program Introduction to, Assay, Silver water disinfection and toxicity 2014V2, Silver: water disinfection and toxicity, Cytology Sample Collection